IRadimed Corp
NASDAQ:IRMD
IRadimed Corp
IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging (MRI) compatible medical devices. The company is headquartered in Winter Springs, Florida and currently employs 110 full-time employees. The company went IPO on 2014-07-16. Its MRidium 3860+ MRI Compatible IV infusion pump system provides non-magnetic Intravenous (IV) infusion pump system that is specifically designed for safe use during MRI procedures. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor with non-ferrous parts and other special features to deliver anesthesia safely and predictably and other IV medications or fluids during various MRI procedures. Its IRadimed 3880 MRI Compatible patient vital signs monitoring system has been designed with non-magnetic components and other features to monitor a patient’s vital signs safely and accurately during various MRI procedures. The firm sells its products primarily to hospitals and acute care facilities, both in the United States and internationally.
IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging (MRI) compatible medical devices. The company is headquartered in Winter Springs, Florida and currently employs 110 full-time employees. The company went IPO on 2014-07-16. Its MRidium 3860+ MRI Compatible IV infusion pump system provides non-magnetic Intravenous (IV) infusion pump system that is specifically designed for safe use during MRI procedures. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor with non-ferrous parts and other special features to deliver anesthesia safely and predictably and other IV medications or fluids during various MRI procedures. Its IRadimed 3880 MRI Compatible patient vital signs monitoring system has been designed with non-magnetic components and other features to monitor a patient’s vital signs safely and accurately during various MRI procedures. The firm sells its products primarily to hospitals and acute care facilities, both in the United States and internationally.
Record Revenue: IRADIMED posted its 17th consecutive quarter of record revenue, reaching $21.2 million for Q3 2025, up 16% from last year.
Pumps & Monitoring Growth: MRI IV pump sales grew 20% year-over-year; MRI patient monitor shipments increased 16%, driving strong overall results.
Gross Margin Strength: Gross margin held at 78% despite manufacturing transition, slightly improving from last year and above expectations.
Guidance Raised: Full-year 2025 revenue guidance increased to $82.5–83.5 million (up from $80–82.5 million); EPS guidance also raised.
3870 Pump Launch: Commercial U.S. launch of the new 3870 MRI IV pump will begin in January 2026, targeting a step-change in pump revenue, especially from replacements.
International Expansion: 3870 launch in Europe and Japan is expected in 2027 after regulatory approvals.
Capacity Secured: New facility is 2.5 times larger and can support significant growth, with room to expand further.
